Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations
Status:
Completed
Trial end date:
2016-04-19
Target enrollment:
Participant gender:
Summary
This study compared the efficacy of indacaterol versus placebo in COPD patients classified as
GOLD 2014 Patient Group B.
This was a 2-arm parallel group study that recruited COPD patients classified by GOLD Patient
Gorup B. On successful completion of run-in period, patients were randomized in the ratio 1:1
to receive prn salbutamol plus:
1. Indacaterol 150ug or
2. Placebo for indacaterol all once daily (od) for 26 weeks. The primary objective (trough
FEV1) was assessed after 12 weeks.